Download MendeleyTarget-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay.
Knoepfel, T., Nimsgern, P., Jacquier, S., Bourrel, M., Vangrevelinghe, E., Glatthar, R., Behnke, D., Alper, P.B., Michellys, P.Y., Deane, J., Junt, T., Zipfel, G., Limonta, S., Hawtin, S., Andre, C., Boulay, T., Loetscher, P., Faller, M., Blank, J., Feifel, R., Betschart, C.(2020) J Med Chem 63: 8276-8295
- PubMed: 32786235
- DOI: https://doi.org/10.1021/acs.jmedchem.0c00130
- Primary Citation of Related Structures:
6TY5 - PubMed Abstract:
Inappropriate activation of endosomal TLR7 and TLR8 occurs in several autoimmune diseases, in particular systemic lupus erythematosus (SLE). Herein, the development of a TLR8 antagonist competition assay and its application for hit generation of dual TLR7/8 antagonists are reported. The structure-guided optimization of the pyridone hit 3 using this biochemical assay in combination with cellular and TLR8 cocrystal structural data resulted in the identification of a highly potent and selective TLR7/8 antagonist ( 27 ) with in vivo efficacy. The two key steps for optimization were (i) a core morph guided by a TLR7 sequence alignment to achieve a dual TLR7/8 antagonism profile and (ii) introduction of a fluorine in the piperidine ring to reduce its basicity, resulting in attractive oral pharmacokinetic (PK) properties and improved TLR8 binding affinity.
Organizational Affiliation:
Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, United States.
